Clinical Trial

Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 13, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of the present study is to study the effect of baricitinib administration on outcome of participants with moderate and severe traumatic intracerebral hemorrhage/contusions. A multi-center randomized control trial will be conducted. Participants with a radiological diagnosis of traumatic intracerebral hemorrhage/contusions and an initial GCS score of 5-12 will be screened and enrolled in the first 24 hours after traumatic brain injury.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-09-26; most recent amendment 2026-04-07.
Status change: Not Yet Recruiting → Recruiting 2025-06-01
Trial Details
NCT Number NCT06065046
Lead Sponsor Tang-Du Hospital
Collaborators: Qianxian People's Hospital, Weinan Central Hospital, Second Affiliated Hospital of Xi'an Jiaotong University, The First Hospital of Yulin, Xidian Group Hospital, Chongqing University Central Hospital & Chongqing Emergency Medical Center, The Peoples' Hospital of Jiaozuo City, First People's Hospital of Xianyang, 987th Hospital of the Chinese People's Liberation Army Joint Logistic Support Force, Chongqing Hospital of PAP, Baoji Fengxiang District Hospital, GEM Flower Xian Changqing Staff Hospital
Conditions Traumatic Brain Injury
Enrollment 100 participants
Start Date 2023-11-24
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-13